Holen Sie sich die Stockscreener-App
0.2749
1.81%
0.0049
Schlusskurs vom Vortag:
$0.27
Offen:
$0.279
24-Stunden-Volumen:
629.70K
Relative Volume:
0.97
Marktkapitalisierung:
$28.42M
Einnahmen:
$1.27M
Nettoeinkommen (Verlust:
$-7.12M
KGV:
-5.2663
EPS:
-0.0522
Netto-Cashflow:
$-5.28M
1W Leistung:
-2.66%
1M Leistung:
-7.10%
6M Leistung:
+3.70%
1J Leistung:
-31.96%
1-Tages-Spanne:
$0.2694
$0.279
1-Wochen-Bereich:
$0.2665
$0.298
52-Wochen-Spanne:
$0.235
$0.4508
IGC Pharma Inc Stock (IGC) Company Profile
Firmenname
IGC Pharma Inc
Sektor
Branche
Telefon
301-983-0998
Adresse
4336 Montgomery Avenue, Bethesda, MD
Compare IGC vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.2749 | 29.20M | 1.27M | -7.12M | -5.28M | -0.0522 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
IGC Pharma Inc Aktie (IGC) Neueste Nachrichten
Press Releases about Ping An Biomedical Co., Ltd.Class A Ordinary Shares (Nasdaq:PASW) - FinancialContent
IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026 - BioBuzz
Each of two children received 100,000 shares as gifts from IGC Pharma (IGC) CEO Ram Mukunda. - Stock Titan
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock. Raising P/T to $4.50." - ACCESS Newswire
2026 Nanocap Stocks to Watch: IGC, KNRX, GYGY, ARAY Lead Watchlist Now See More Inside! - openPR.com
IGC Pharma Completes Enrollment in CALMA Phase 2 Trial for Alzhe - GuruFocus
168 people are enrolled in a trial for Alzheimer's-related agitation. Results are expected in 2026's final quarter. - Stock Titan
PullBack Stocks PDSB, PRSO, IGC, RETO: Who Breaks First? - openPR.com
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75." - ACCESS Newswire
IGC Pharma Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
IGC Q1 2026 Earnings: Narrower-Than-Expected Loss as Clinical-Stage Pipeline Stays in FocusWeak Earnings Momentum - careplusvn.com
IGC Pharma Evaluates Recovery After Left Verdict - ACCESS Newswire
Price to earnings forward of IGC Pharma, Inc. – AMEX:IGC - TradingView
IGC Pharma (NYSE: IGC) Target Raised on Alzheimer's 2027 Outlook - marketscreener.com
IGC Pharma (IGC) Slips to $0.31 as Key Support Comes into FocusMerger Arbitrage - dars.gov.et
Nasdaq 30's VIVS, IGC, RIME, AIXI Stocks Now - openPR.com
Nasdaq 30’s VIVS, IGC, RIME, AIXI Stocks Now - FinancialContent
IGC Q1 2026 Earnings: Narrower Loss Beats Estimates as Pipeline Progress Supports SentimentMargin Improvement Report - careplusvn.com
IGC (IGC) Technicals: Falls 0.65% to $0.31 on the Day; Level Watch: $0.29 and $0.33 Define the Nearby Reference Levels in the Latest ReadingLarge Cap Trends - vinanet.vn
MicroCaps IGC, BIVI, ORBS, RIME Sub-$1 Stocks to Watch Now - openPR.com
IGC Pharma earnings matched, revenue fell short of estimates By Investing.com - Investing.com India
IGC (IGC) Earnings Data Review: The Bottom-Line Figure Outpaces Its Comparison at the Close; Session Reaction: Shares Move 1.43% Higher in the Current UpdatePost-Earnings Reaction - vinanet.vn
IGC Pharma earnings matched, revenue fell short of estimates - Investing.com
IGC Pharma Releases Q2 2026 Financial Results - AlphaStreet
VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum - openPR.com
IGC Pharma execs buy 4.27M shares to settle $1.15M debt - scanx.trade
IGC Pharma Q2 Results: Sales up 39% YoY, EPS loss widens to $(0.03) - scanx.trade
IGC Looks 24.1% Overvalued on GF Value™ - GuruFocus
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure - Finviz
IGC Pharma Q2 Results: CALMA Nears Enrollment Closure - accessnewswire.com
IGC Pharma, Inc. 2026: Revenue $265K, EPS ($0.03) — 10-Q Summary - TradingView
IGC Pharma (NYSE: IGC) widens loss while Phase 2 Alzheimer’s trial hits key milestone - Stock Titan
IGC Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Microcaps TOON, IGC, SURG, MDXH to Watch Now as Earnings, AI and Biotech Catalysts Build - openPR.com
IGC Pharma (NYSE American:IGC): What Does the Latest Update Mean for Clinical Development? - Kalkine Media
IGC Pharma Inc (IGC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
IGC Pharma (NYSE AMERICAN:IGC): What Could Today’s regulatory execution Update Reveal? - Kalkine Media
IGC Pharma (NYSE AMERICAN:IGC): What Could Today’s cannabinoid research progress Update Reveal? - Kalkine Media
Early Alert: PLAG, PRSO, UZX, IGC Lead Sub-$1 Stocks to WatchPlus More in Focus - openPR.com
Early Alert: PLAG, PRSO, UZX, IGC Lead Sub-$1 Stocks to Watch – Plus More in Focus - FinancialContent
IGC Looks 21.6% Overvalued on GF Value™ - GuruFocus
IGC Pharma Advances CALMA Toward Q4 Topline Readout - ACCESS Newswire
IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout - Corsicana Daily Sun
IGC Pharma Inc (IGS1.DU) balance sheet - Yahoo Finance UK
Enterprise value to revenue forward of IGC Pharma, Inc. – AMEX:IGC - TradingView
IGC Pharma Inc (IGC) Stock News Today - TradingKey
Price to sales forward of IGC Pharma, Inc. – MUN:IGS1 - TradingView
Bullish Volume: RITR, IGC, BJDX, CISS Lead Active Sub-$1 Stocks to Watch - openpr.com
IGC Q1 2026 Earnings: Narrower-Than-Expected Loss Marks 14.16% EPS BeatSaaS Earnings Trends - careplusvn.com
Microcaps MGRX, PRSO, IGC, KUST In the News to Watch - openPR.com
IGC Pharma, Inc. Revenue Breakdown – AMEX:IGC - TradingView
Finanzdaten der IGC Pharma Inc-Aktie (IGC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):